• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 感染对囊性纤维化患者肺功能和营养状况的影响:一项全球队列研究。

Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.

机构信息

Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.

UK Trust, London, United Kingdom.

出版信息

J Cyst Fibros. 2024 Sep;23(5):815-822. doi: 10.1016/j.jcf.2024.07.019. Epub 2024 Aug 26.

DOI:10.1016/j.jcf.2024.07.019
PMID:39191560
Abstract

BACKGROUND

Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF).

METHODS

This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection.

RESULTS

A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection.

CONCLUSIONS

No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.

摘要

背景

已确定与严重 COVID-19 感染相关的因素;然而,感染对长期结果的影响尚不清楚。本研究的目的是研究 COVID-19 感染对囊性纤维化(pwCF)患者肺功能和营养状况轨迹的影响。

方法

这是一项回顾性全球队列研究,纳入了 2020 年 1 月 1 日至 2021 年 12 月 31 日期间确诊 COVID-19 感染的 pwCF。记录确诊 COVID-19 前 12 个月和确诊后 12 个月的一秒用力呼气容积占预计值的百分比(ppFEV)和体重指数(BMI)。使用 t 检验比较平均 ppFEV 和 BMI 的变化。使用线性混合效应模型估计随时间的变化,并比较感染前后的变化率。

结果

共纳入 33 个国家的 6500 例 pwCF 感染 COVID-19 的病例进行分析。感染前后 ppFEV 的平均差异为 1.4%(95%CI,1.1%,1.7%)。在未服用调节剂的患者中,感染前后变化率的差异为 1.34%(95%CI,-0.88%,3.56%)/年(p=0.24)和-0.74%(-1.89%,0.41%)/年(p=0.21),对于服用 elexacaftor/tezacaftor/ivacaftor 的患者。感染 COVID-19 前后,BMI 或 BMI 百分位数无临床意义的变化。

结论

在感染 COVID-19 后的一年中,未发现肺功能和 BMI 轨迹有临床意义的影响。这项工作突出了全球 CF 社区团结起来解决 pwCF 面临的关键问题的能力。

相似文献

1
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.COVID-19 感染对囊性纤维化患者肺功能和营养状况的影响:一项全球队列研究。
J Cyst Fibros. 2024 Sep;23(5):815-822. doi: 10.1016/j.jcf.2024.07.019. Epub 2024 Aug 26.
2
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对具有 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(含或不含增效剂)。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3.
3
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).针对携带 II 类 CFTR 基因突变(最常见的是 F508del)的囊性纤维化患者的校正治疗(有或没有增效剂)。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4.
4
Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.依伐卡托与泰他卡托和艾克那肽三联复方治疗伴晚期肺部疾病的囊性纤维化成人患者的多系统作用
Ann Am Thorac Soc. 2024 Jul;21(7):1053-1064. doi: 10.1513/AnnalsATS.202312-1065OC.
5
Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.在不符合临床试验条件的囊性纤维化患者中使用依列卡福-替扎卡福-依伐卡福:一项为期24周的观察性研究。
Front Pharmacol. 2023 Jun 2;14:1178009. doi: 10.3389/fphar.2023.1178009. eCollection 2023.
6
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者肺功能、营养状况、肺部恶化频率及汗液氯化物的影响:来自德国囊性纤维化登记处的真实世界证据
Lancet Reg Health Eur. 2023 Jul 28;32:100690. doi: 10.1016/j.lanepe.2023.100690. eCollection 2023 Sep.
7
Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.囊性纤维化和晚期肺病患者从 lumacaftor/ivacaftor 治疗中获益。
Pediatr Pulmonol. 2020 Dec;55(12):3364-3370. doi: 10.1002/ppul.25059. Epub 2020 Sep 19.
8
Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis.COVID-19 大流行期间囊性纤维化患者的护理变化。
Ann Am Thorac Soc. 2022 Oct;19(10):1697-1703. doi: 10.1513/AnnalsATS.202105-532OC.
9
Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.依洛尤单抗治疗伴有进展性肺部疾病的成年囊性纤维化患者的长期临床结局。
Respir Med. 2023 Nov-Dec;219:107406. doi: 10.1016/j.rmed.2023.107406. Epub 2023 Sep 9.
10
A pre-post retrospective study of patients with cystic fibrosis and gastrostomy tubes.囊性纤维化和胃造口管患者的前后回顾性研究。
J Pediatr Gastroenterol Nutr. 2011 Oct;53(4):453-8. doi: 10.1097/MPG.0b013e3182250c43.

引用本文的文献

1
Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.囊性纤维化患儿中肺功能正常的单纯性新型冠状病毒感染:一项为期三年的单中心经验
J Clin Med. 2025 Apr 25;14(9):2979. doi: 10.3390/jcm14092979.
2
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: Impact on Hospitalizations and Health Care Resource Utilization in a Universal Health Care Setting.依列卡福妥/替扎卡福妥/依伐卡托治疗囊性纤维化:在全民医保环境下对住院率和医疗资源利用的影响
Pulm Ther. 2025 Jun;11(2):235-247. doi: 10.1007/s41030-025-00287-1. Epub 2025 Feb 13.